

REMARKS

Claims 1-12 are pending.

Claims 1-4 are elected with traverse.

Claims 5-12 are withdrawn.

Responsive to the restriction requirement set forth in the Office action, the Applicants elect Group 1, claims 1-4. The single species elected for searching purposes is example 172, formula (196) found on page 23 of disclosure.

The Examiner states that Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features that define a contribution over the prior art.

The Examiner is of the opinion that the technical feature in common in all the invention groups is the triazine core formula[with various groups, which are attached directly or indirectly to the core formula] novel compounds

The Applicants traverse the above restriction because the compounds of formula (1) are novel. As novel compounds, their process for preparation, compositions containing them and methods of using them are novel. Thus the Applicants believe that the Examiner has inappropriately considered the various groups which are attached directly or indirectly to the core formula in light of US 5,929,215.

In the event that the compositions are determined to be novel during prosecution and allowed, the Applicants will respectfully request that Group 1 be rejoined to Groups II thru IV.

For all of the above reasons, reconsideration and withdrawal of the restriction requirement is respectfully solicited.

On finding claims directed to the elected species to be allowable, withdrawal of the election requirement and consideration of the patentability of the remainder of the Markush group is also respectfully solicited.

An examination on the merits of the claims is respectfully awaited.

Respectfully submitted,



Ciba Specialty Chemicals Corporation
540 White Plains Road
Tarrytown, New York 10591
(914) 785-2768
SAL22723Rest.doc

Sheila A. Loggins
Agent for Applicants
Reg. No. 56,221